🟢 Edesa Biotech is trading 6.87% up in after-hours trading after argenx’s $2.2 billion Forte acquisition

Edesa Biotech is trading 6.87% up now at $5.60 after positive immunology-sector sentiment linked to argenx’s agreement to acquire Forte Biosciences for approximately $2.2 billion.

• The transaction includes a $77-per-share cash tender offer and expands argenx’s vitiligo and autoimmune pipeline.
• Edesa Biotech closed August 10 at $5.24; no company-specific announcement or earnings release was identified.
• Broader indexes were mixed to slightly lower, limiting evidence of a global market catalyst.